Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025

Allogene Therapeutics reported positive Phase 1 TRAVERSE trial data for ALLO-316, an allogeneic CAR T cell therapy targeting CD70 in advanced renal cell carcinoma (RCC). A single dose of ALLO-316 achieved a 31% confirmed response rate in patients with a CD70 tumor proportion score of 50% or higher, with four of five responders maintaining their response, including one in remission for over 12 months. The trial demonstrated robust CAR T cell expansion and tumor infiltration, with a manageable safety profile, suggesting ALLO-316's potential to address unmet needs in RCC patients who have not responded to existing therapies; the FDA previously granted ALLO-316 Regenerative Medicine Advanced Therapy (RMAT) designation.

Analysis

Allogene Therapeutics' ALLO-316 has demonstrated promising early clinical activity in its Phase 1 TRAVERSE trial for advanced or metastatic renal cell carcinoma (RCC), achieving a 31% confirmed overall response rate in patients with a CD70 tumor proportion score (TPS) of 50% or higher. Notably, four of five confirmed responders maintained their responses, with one patient in ongoing remission for over 12 months, suggesting potential for durable benefit. The therapy, utilizing Dagger® technology for robust CAR T cell expansion, showed manageable safety, primarily characterized by hematologic adverse events, with no treatment-related Grade 5 events; cytokine release syndrome (CRS) occurred in 68% of patients (no grade ≥3) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 18% (no grade ≥3). The FDA's granting of Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations underscores the potential to address unmet needs. However, these are Phase 1 results, and efficacy in larger studies remains to be confirmed. Contrasting with the clinical optimism, significant insider selling has occurred over the past six months, with 12 sales and zero purchases by company executives, including the CEO, EVP of R&D, and CFO, totaling a considerable number of shares. Institutional ownership changes in Q1 2025 were mixed: FMR LLC and State Street Corp significantly reduced their positions by 68.9% and 61.5% respectively, and Perceptive Advisors LLC exited entirely in Q4 2024, while Darwin Global Management, Capital World Investors, Citadel Advisors, and Goldman Sachs Group Inc initiated or substantially increased their holdings. This divergence indicates varied institutional sentiment despite the positive early trial data and regulatory support.

Key Decisions for Investors

• Investors should weigh the promising, albeit early-stage, Phase 1 clinical data for ALLO-316 against the significant and consistent insider selling activity observed over the past six months.
• Monitor upcoming clinical trial milestones, particularly data from larger patient cohorts and further regulatory interactions, to validate the initial efficacy and safety signals before committing significant capital.
• Note the mixed institutional investor sentiment, with major funds both increasing and decreasing stakes, reflecting underlying uncertainty and the high-risk, high-reward profile typical of clinical-stage biotechnology companies.
• Closely scrutinize the company's ability to manage potential adverse events and scale its Dagger® technology as development progresses into later-stage trials.